Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $940,000.

  • Heron Therapeutics' Cash from Financing Activities rose 95350.00% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 1943.44%. This contributed to the annual value of $940,000 for FY2024, which is 98.26% down from last year.
  • As of FY2024, Heron Therapeutics' Cash from Financing Activities stood at $940,000, which was down 98.26% from $54.1 million recorded in FY2023.
  • Over the past 5 years, Heron Therapeutics' Cash from Financing Activities peaked at $156.0 million during FY2021, and registered a low of $940,000 during FY2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was $54.1 million (2023), whereas its average is $43.4 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first spiked by 1,613.65% in 2021, then tumbled by 98.26% in 2024.
  • Over the past 5 years, Heron Therapeutics' Cash from Financing Activities (Yearly) stood at $9.1 million in 2020, then spiked by 1,613.65% to $156.0 million in 2021, then tumbled by 51.89% to $75.1 million in 2022, then declined by 27.91% to $54.1 million in 2023, then crashed by 98.26% to $940,000 in 2024.